RYBREVANT® (AMIVANTAMAB-VMJW) LONGER-TERM RESULTS SHOW PROMISING AND DURABLE RESPONSES IN DIFFICULT-TO-TREAT COLORECTAL CANCER
J&J - OVER 70% RESPONSE RATE IN FIRST-LINE SUBGROUP WITH AMIVANTAMAB
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.